Ribavirin and IFN-α combination therapy induces CD4+ T-cell proliferation and Th1 cytokine secretion in patients with chronic hepatitis B

Table 1 Clinical characteristics of patients at enrollment

Patient No.	Age(yr)	Gender	ALT(nkat/L)	HBV DNA(103 LGE/L)	Type of response(end of treatment)
Group A
1	48	M	89	6.8	Responder
2	51	M	158	7.3	Responder
3	44	M	86	8.3	Responder
4	41	M	464	8.0	Responder
5	39	M	122	4.8	Responder
6	67	M	142	8.1	Non-responder
7	52	M	140	8.3	Non-responder
8	26	M	69	4.8	Non-responder
9	52	M	46	7.6	Non-responder
10	33	M	39	5.4	Non-responder
11	24	F	458	8.7	Non-responder
12	27	F	51	8.5	Non-responder
13	52	F	80	7.4	Non-responder
14	37	F	57	6.8	Non-responder
Group B
15	42	F	43	7.2	No treatment
16	33	F	19	8.1	No treatment
17	51	M	138	3.9	No treatment
18	31	M	57	7.1	No treatment
19	29	M	79	7.1	No treatment
20	44	M	46	7.2	No treatment

P > 0.05, Group A vs Group B.